Trial Profile
A First-in-human Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of BNZ132-1-40
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Sep 2019
Price :
$35
*
At a glance
- Drugs EQ 101 (Primary)
- Indications Adult T-cell leukaemia-lymphoma; Alopecia areata; Cutaneous T-cell lymphoma; Large granular lymphocytic leukaemia; T-cell leukaemia
- Focus Adverse reactions; First in man
- Sponsors Bioniz
- 29 Aug 2019 Interim results assessing safety of BNZ-1 published in the Journal of Clinical Pharmacology
- 12 Dec 2017 Results assessing safety and tolerability, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 02 Nov 2017 According to a Bioniz media release, new data will be presented at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition.